Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Express Scripts
McKinsey
Mallinckrodt
Moodys

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR DATSCAN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Datscan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00129181 ↗ Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease Completed GE Healthcare N/A 2005-01-01 This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00129181 ↗ Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease Completed Pfizer N/A 2005-01-01 This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00129181 ↗ Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease Completed Institute for Neurodegenerative Disorders N/A 2005-01-01 This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00209456 ↗ Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed GE Healthcare Phase 3 2003-11-01 The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical diagnosis of an independent expert consensus panel used as the standard of truth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Datscan

Condition Name

Condition Name for Datscan
Intervention Trials
Parkinson Disease 4
Parkinsonian Syndrome 2
REM Sleep Behavior Disorder 2
Vascular Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Datscan
Intervention Trials
Parkinson Disease 8
Parkinsonian Disorders 4
Lewy Body Disease 3
Dementia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Datscan

Trials by Country

Trials by Country for Datscan
Location Trials
United States 24
China 7
Germany 3
Austria 2
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Datscan
Location Trials
Connecticut 3
Florida 3
California 2
Arizona 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Datscan

Clinical Trial Phase

Clinical Trial Phase for Datscan
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Datscan
Clinical Trial Phase Trials
Completed 7
Enrolling by invitation 3
Recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Datscan

Sponsor Name

Sponsor Name for Datscan
Sponsor Trials
GE Healthcare 5
PPD 2
Institute for Neurodegenerative Disorders 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Datscan
Sponsor Trials
Other 24
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Moodys
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.